Scientific instruments company Waters Corporation (NYSE: WAT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 113% year on year to $1.65 billion. The company expects next quarter’s revenue to be around $1.75 billion, close to analysts’ estimates. Its non-GAAP profit of $3.05 per share was 1.4% above analysts’ consensus estimates.

Is now the time to buy WAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The company also credited cross-divisional collaboration and improvements in commercial execution for boosting performance.

Looking ahead, Waters Corporation’s guidance is shaped by expectations for continued growth across its legacy and acquired divisions, with new product launches and operational efficiencies anticipated to drive performance. Management emphasized the importance of replacement cycles and the ramp-up of recent acquisitions, particularly the launch of the FACSDiscover A7 and BACTEC FXI platforms. CFO Amol Chaubal noted that the company’s cost actions are expected to yield $75 million in savings this year, supporting margin expansion in the second half. Waters also sees opportunities tied to reshoring trends and ongoing pricing discipline.

Key Insights from Management’s Remarks

Management attributed Q2’s outperformance to a combination of organic growth, the rapid integration of acquired businesses, and early success from new product introductions.

• Acquired business momentum: Waters’ newly acquired Biosciences and Diagnostic Solutions segments posted a marked improvement in growth trajectory, with mid-single-digit gains. Management credited disciplined execution of a 180-day revitalization plan and early realization of revenue synergies for the turnaround.
• Product innovation impact: The launch of new mass spectrometry (MS) and chromatography products, such as the Cyclic IMS P20 and Xevo MRT P10, contributed to increased demand from both pharmaceutical and academic customers. These instruments offer enhanced sensitivity and throughput, which management believes are differentiating in competitive markets.
• Pricing discipline and compliance: Waters implemented pricing increases and a new deal desk approach across its acquired portfolio, achieving 90 basis points of net price realization in the quarter. Enhanced compliance management in reagent rental contracts is expected to further bolster profitability.
• China performance and localization: Despite ongoing headwinds in China, especially in diagnostics, Waters saw improvements due to localized manufacturing and leadership changes. The company expects the full flow cytometry portfolio and localized diagnostic products to drive growth in China in upcoming quarters.
• Replacement cycle and reshoring: Instrument replacement cycles in pharma and diagnostics, as well as capital investment in U.S. pharmaceutical manufacturing (“reshoring”), are seen as structural tailwinds. Management noted that roughly 70% of tracked U.S. pharma expansion sites are existing Waters customers, positioning the company to benefit as these sites ramp up equipment purchases.

Drivers of Future Performance

Waters’ outlook for the next quarter and year centers on sustained growth from recent acquisitions, enhanced pricing, and new product launches, balanced against foreign exchange and cost headwinds.

• New product launches: The upcoming commercial release of FACSDiscover A7 and the rollout of BACTEC FXI in diagnostic markets are expected to drive incremental sales, particularly as these products address unmet needs in high-throughput labs and clinical testing.
• Operational efficiencies and cost savings: Management anticipates $75 million in cost savings for 2026 through restructuring and supply chain optimization, supporting margin progression even as revenue grows. These actions are expected to have a lasting impact, with a $200 million run-rate benefit projected.
• Reshoring and replacement cycles: Increased U.S. pharmaceutical manufacturing investment and the ongoing instrument replacement cycle are likely to provide Waters with additional revenue streams. Management believes this will be especially relevant from 2027 onward, as construction of new facilities translates into demand for advanced analytical and diagnostic equipment.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be watching (1) the pace of adoption and customer feedback for the FACSDiscover A7 and BACTEC FXI launches, (2) whether localized manufacturing and leadership changes in China can turn recent improvements into sustained growth, and (3) tangible progress on reshoring-driven equipment demand in the U.S. Further, we will monitor the company’s ability to execute on pricing and cost-control initiatives as margin pressures persist.

Waters Corporation currently trades at $395.96, up from $374.74 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.